Texas Instruments stock faces a Tuesday gut-check as tariffs rattle tech and earnings loom
20 January 2026
1 min read

Texas Instruments stock faces a Tuesday gut-check as tariffs rattle tech and earnings loom

New York, January 19, 2026, 19:04 EST — Market closed.

  • U.S. markets reopen Tuesday following the Martin Luther King Jr. Day holiday, as Nasdaq futures dip on new tariff news.
  • Wall Street raised targets for Texas Instruments as the week begins, though analysts remain cautious ahead of the company’s late-January earnings report.

Shares of Texas Instruments Incorporated will restart trading Tuesday following the U.S. holiday pause, while Nasdaq 100 futures dropped 1.25% amid President Donald Trump’s threat of wider tariffs on European nations. 1

This is crucial for Texas Instruments since its stock is seen as a gauge for demand in industrial and automotive electronics. Investors, with earnings season approaching, have little tolerance for unexpected developments.

A risk-off start will put last week’s analyst optimism to the test, challenging whether buyers stick around if the market sours.

Texas Instruments closed at $191.58, marking a roughly 1.3% gain from the previous day. The stock swung between $189.80 and $192.47 during the last session, with trading volume around 6.9 million shares.

Stifel analyst Tore Svanberg raised his price target on Texas Instruments to $200 from $170, maintaining a Hold rating in a quarterly preview covering the company’s “analog, connectivity and processors” segments. He noted a rebound in “analog appetite,” alongside sustained strength in AI infrastructure and the growing feasibility of edge AI. 2

Wells Fargo’s Joe Quatrochi bumped his price target to $185 from $170 while maintaining an Equal Weight rating. He pointed to updated industry models and a strong focus on industrial and electrical signals linked to AI-driven demand. 3

Texas Instruments announced its board has approved a quarterly cash dividend of $1.42 per share. The payout is set for Feb. 10, with the record date on Jan. 30, the company confirmed. 4

The near-term outlook is mixed. A weaker macro backdrop, coupled with any escalation on tariff threats, might weigh on sentiment throughout global supply chains. This could impact chipmakers tied more to the sluggish industrial sector, not just those riding the flashy wave of AI demand.

The next batch of company earnings carries greater uncertainty. Should management hint at a slower recovery in industrial orders, or if manufacturing costs squeeze margins, the stock’s premium valuation could face tougher scrutiny.

Texas Instruments plans to webcast its Q4 and full-year 2025 earnings call on Tuesday, Jan. 27 at 3:30 p.m. Central. Chairman, president, and CEO Haviv Ilan will lead the discussion, joined by CFO Rafael Lizardi and head of investor relations Mike Beckman. 5

Stock Market Today

Philip Morris stock price: PM steadies near $183 after upbeat 2026 forecast puts Zyn battle back in view

Philip Morris stock price: PM steadies near $183 after upbeat 2026 forecast puts Zyn battle back in view

7 February 2026
New York, Feb 7, 2026, 15:18 EST — Market closed. Philip Morris International shares last stood at $182.81, up 0.45% from the prior session, after the company laid out a higher 2026 profit outlook tied to its nicotine pouch business. 1 That matters now because the stock has become a referendum on whether smoke-free products can keep carrying earnings while the category gets crowded. Zyn is the big swing factor, and traders are watching for any sign that volume gains are coming at the cost of pricing power. With U.S. markets shut for the weekend, the next test comes at
AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
ASML stock price drops 4% on Trump tariff threat — what to watch next
Previous Story

ASML stock price drops 4% on Trump tariff threat — what to watch next

SK hynix stock price: Tariff headlines and Jan 29 earnings keep 000660.KS in play
Next Story

SK hynix stock price: Tariff headlines and Jan 29 earnings keep 000660.KS in play

Go toTop